Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial

被引:2
作者
Ren, Chao [1 ]
Mai, Zong-Jiong [1 ]
Jin, Ying [1 ]
He, Ming-Ming [1 ]
Wang, Zhi-Qiang [1 ]
Luo, Hui-Yan [1 ]
Zhang, Dong-Sheng [1 ]
Wu, Chen-Yi [1 ]
Wang, Feng [1 ]
Xu, Rui-Hua [1 ]
机构
[1] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Dept Med Oncol, Guangzhou 510060, Peoples R China
基金
中国国家自然科学基金;
关键词
Apatinib; immunotherapy; metastatic colorectal cancer; microsatellite stable; SHR-1210; INHIBITOR;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the REGONIVO study, regorafenib combined with nivolumab was effective in the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC), which indicated anti-angiogenic drugs may enhance the efficacy of immune checkpoint inhibitors. Therefore, we designed a single-arm, single-center, open-label, phase II trial to determine the toxicity and efficacy of SHR-1210 (an anti-PD-1 antibody) plus apatinib in MSS mCRC. The sample size was estimated using a Simon Optimum two stage design. 10 patients were included at the first stage and if one effective patient observed, an additional 19 patients would be added. Patients with MSS mCRC who refractory to second-line treatment or intolerant to standard treatment were given SHR-1210 200 mg every 2 weeks and apatinib 250-375 mg once daily until unacceptable toxicity or disease progression occurred. In our study, the objective response rate was 0% and the disease control rate was 22.2%. The median progression-free survival was 1.83 months (95% confidence interval (CI) 1.80-1.86 months), and the median overall survival was 7.80 months (95% CI 0-17.07). Treatment-related adverse events (AEs) occurred in all patients (100%). The most common treatment-related AEs were hypertension and proteinuria (70% each). Grade 3 AEs were observed in nine patients (9/10, 90%), and the commonest was hypertension (30%). In conclusion, SHR-1210 combined with apatinib has failed to improve the efficacy of treatment of MSS mCRC, and the intolerable toxicity may be the leading cause.
引用
收藏
页码:2946 / +
页数:11
相关论文
共 50 条
[41]   A study protocol for an open-label, single-arm, single-center phase I clinical study on tolerability, safety, and efficacy of dalpiciclib combined with apatinib in the treatment of patients with advanced or metastatic sarcoma [J].
Huang, Huiying ;
Zhang, Hua ;
Cao, Baoshan .
THORACIC CANCER, 2024, 15 (05) :427-433
[42]   Raltitrexed, S-1 and fruquintinib (RSF) in the treatment of refractory metastatic colorectal cancer: study protocol for a multicenter, prospective, single-arm, phase II trial [J].
Leng, Weibing ;
Wen, Zhenpeng ;
Wang, Han ;
Cao, Peng ;
Liu, Jiyan ;
Luo, Deyun ;
Qiu, Meng .
BMC CANCER, 2025, 25 (01)
[43]   Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2) [J].
Yang, Guangjian ;
Xu, Haiyan ;
Yang, Yaning ;
Zhang, Shuyang ;
Xu, Fei ;
Hao, Xuezhi ;
Li, Junling ;
Xing, Puyuan ;
Hu, Xingsheng ;
Liu, Yutao ;
Wang, Lin ;
Lin, Lin ;
Wang, Zhijie ;
Duan, Jianchun ;
Wang, Jie ;
Wang, Yan .
BMC MEDICINE, 2022, 20 (01)
[44]   Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study [J].
Van Cutsem, Eric ;
Martinelli, Erika ;
Cascinu, Stefano ;
Sobrero, Alberto ;
Banzi, Maria ;
Seitz, Jean-Francois ;
Barone, Carlo ;
Ychou, Marc ;
Peeters, Marc ;
Brenner, Baruch ;
Hofheinz, Ralf Dieter ;
Maiello, Evaristo ;
Andre, Thierry ;
Spallanzani, Andrea ;
Garcia-Carbonero, Rocio ;
Arriaga, Yull E. ;
Verma, Udit ;
Grothey, Axel ;
Kappeler, Christian ;
Miriyala, Ashok ;
Kalmus, Joachim ;
Falcone, Alfredo ;
Zaniboni, Alberto .
ONCOLOGIST, 2019, 24 (02) :185-192
[45]   Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2) [J].
Guangjian Yang ;
Haiyan Xu ;
Yaning Yang ;
Shuyang Zhang ;
Fei Xu ;
Xuezhi Hao ;
Junling Li ;
Puyuan Xing ;
Xingsheng Hu ;
Yutao Liu ;
Lin Wang ;
Lin Lin ;
Zhijie Wang ;
Jianchun Duan ;
Jie Wang ;
Yan Wang .
BMC Medicine, 20
[46]   Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial [J].
Zhou, Na ;
Zhang, Chuantao ;
Liu, Dong ;
Liu, Kewei ;
Wang, Guanqun ;
Zhu, Hua ;
Zhang, Jianli ;
Jiang, Man ;
Liu, Ning ;
Zhang, Xiaochun .
ONCOLOGIST, 2021, 26 (03) :E374-E381
[47]   Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial [J].
Jie Chen ;
Chen Li ;
Yuanjie Cao ;
Li Zhu ;
Bailin Zhang ;
Jinqiang You ;
Hailing Hou ;
Jing Wang ;
Zhiyong Yuan .
BMC Cancer, 22
[48]   Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study [J].
Wei, Qing ;
Xu, Xiaoqing ;
Li, Jingjing ;
Wang, Chang ;
Chen, Weijun ;
Xie, Yanru ;
Luo, Cong ;
Chen, Lei ;
Chu, Jiadong ;
Wu, Wei ;
Han, Zhe ;
Yang, Yanlian ;
Hu, Zhiyuan ;
Xu, Qi ;
Ying, Jieer .
ONCOLOGIST, 2024, 29 (04) :e364-e578
[49]   Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial [J].
Chen, Li ;
Jiang, Yi-Zhou ;
Wu, Song-Yang ;
Wu, Jiong ;
Di, Gen -Hong ;
Liu, Guang-Yu ;
Yu, Ke-Da ;
Fan, Lei ;
Li, Jun-Jie ;
Hou, Yi-Feng ;
Hu, Zhen ;
Chen, Can-Ming ;
Huang, Xiao-Yan ;
Cao, A-Yong ;
Hu, Xin ;
Zhao, Shen ;
Ma, Xiao-Yan ;
Xu, Ying ;
Sun, Xiang-Jie ;
Chai, Wen -Jun ;
Guo, Xiaomao ;
Chen, Xizi ;
Xu, Yanhui ;
Zhu, Xiao-Yu ;
Zou, Jian-Jun ;
Yang, Wen-Tao ;
Wang, Zhong-Hua ;
Shao, Zhi-Ming .
CLINICAL CANCER RESEARCH, 2022, 28 (13) :2807-2817
[50]   Efficacy and safety of cadonilimab combined with chemotherapy as the first-line treatment for primary advanced or recurrent endometrial cancer: a prospective single-arm open-label phase II clinical trial [J].
Lin, Jie ;
Liu, Tongyu ;
Chen, Jian ;
Lin, Yingtao ;
Chen, Xiaoxiang ;
Zhuo, Yanhong ;
Li, Yuzhi ;
Jiang, Yu ;
Yang, Linlin ;
Tu, Chunhua ;
Liu, Bin ;
Zou, Jianping ;
Chen, Lijun ;
Sun, Yang .
BMJ OPEN, 2025, 15 (05)